Pulmocide

aid: pulmocide
name: Pulmocide
description: 'Pulmocide Ltd. is a privately held, clinical-stage biopharmaceutical company headquartered at 44 Southampton
  Buildings in London, United Kingdom, with a US entity (Pulmocide Inc.) in Boston, Massachusetts. It develops novel inhaled
  medicines for pulmonary aspergillosis and other difficult-to-treat respiratory diseases, delivering drug directly to the
  site of infection in the lung to achieve high local exposure with low systemic exposure. Its lead asset is opelconazole
  (formerly PC945), an inhaled triazole antifungal active against Aspergillus that has received US FDA Orphan Drug, Fast Track
  and Qualified Infectious Disease Product designations; the company reported Phase 2 OPERA-S safety results in 2024 and announced
  termination of the Phase 3 OPERA-T study in 2025. Pulmocide is a drug developer, not a software or platform company: it
  publishes no developer program, no public API, no SDKs and no machine-readable API contract of any kind. This profile therefore
  records identity, corporate web properties and probed absence rather than API artifacts.'
url: https://raw.githubusercontent.com/api-evangelist/pulmocide/refs/heads/main/apis.yml
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://pulmocide.com/wp-content/uploads/2023/08/PULM_OG_Facebook.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Clinical Trials
- Respiratory
- Antifungal
- Drug Development
- Healthcare
- United Kingdom
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: LLMsTxt
  url: llms/pulmocide-llms.txt
- type: DomainSecurity
  url: security/pulmocide-domain-security.yml
- type: Website
  url: https://pulmocide.com/
- type: About
  url: https://pulmocide.com/about-us/
- type: Contact
  url: https://pulmocide.com/contact/
- type: News
  url: https://pulmocide.com/in-the-news/
- type: BlogRSS
  url: https://pulmocide.com/feed/
- type: Investors
  url: https://pulmocide.com/investors-and-partners/
- type: PrivacyPolicy
  url: https://pulmocide.com/privacy-notice/
- type: CookiePolicy
  url: https://pulmocide.com/cookie-policy/
- type: Accessibility
  url: https://pulmocide.com/accessibility/
x-enrichment:
  date: '2026-08-26'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Pulmocide Ltd. is a clinical-stage biopharmaceutical company whose product is an inhaled antifungal drug (opelconazole),
    not software; its only web property is a twelve-page WordPress marketing site with no developer section, and every contract-discovery
    path on pulmocide.com (/openapi.json, /graphql, /llms.txt, every /.well-known/*) returned 404 while the site's stock WordPress
    /wp-json/ discovery root is default CMS plumbing rather than an API the company ships.
  evidence:
  - url: https://pulmocide.com/openapi.json
    status: 404
  - url: https://pulmocide.com/graphql
    status: 404
  - url: https://pulmocide.com/llms.txt
    status: 404
  - url: https://pulmocide.com/.well-known/agent-card.json
    status: 404
  - url: https://pulmocide.com/wp-json/
    status: 200
  - url: https://github.com/pulmocide
    status: 404
  checked: '2026-08-26'